Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesThe efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis
JACC - Journal of the American College of Cardiology, 08/13/09
O'Donoghue M et al. – Prasugrel significantly reduces the risk of cardiovascular events in pts with acute coronary syndromes after percutaneous coronary intervention, regardless of glycoprotein (GP) IIb/IIIa inhibitor use.
Methods- Study of efficacy and safety of prasugrel and clopidogrel in setting of glycoprotein (GP) IIb/IIIa inhibitor use
- TRITON–TIMI 38: randomization of 13,608 subjects with acute coronary syndrome undergoing percutaneous coronary intervention to prasugrel vs clopidogrel
- GP IIb/IIIa inhibitor use at physician's discretion
- Endpoints examined at 30 days and stratified by GP IIb/IIIa inhibitor use
- GP IIb/IIIa inhibitor during index hospitalization for 7,414 subjects (54.5%)
- Consistent benefit of prasugrel vs clopidogrel for reducing cardiovascular death, myocardial infarction, or stroke in pts treated/not treated with GP IIb/IIIa inhibitor
- Prasugrel significantly reduced myocardial infarction, urgent revascularization, and stent thrombosis irrespective of GP IIb/IIIa inhibitor use
- Bleeding rates greater with GP IIb/IIIa inhibitor use
- For prasugrel vs clopidogrel, no significant difference in pts treated/not treated with GP IIb/IIIa inhibitor for risk of thrombolysis in myocardial infarction major or minor bleeding
Related Articles
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors
Atherosclerosis, 11/13/09
Relevance Score: 80%
Dual antiplatelet therapy in coronary artery disease: A case-based approach
Cleveland Clinic Journal of Medicine, 11/04/09
Relevance Score: 79%
New antiplatelet agents: Why they are needed
European Journal of Internal Medicine, 11/09/09
Relevance Score: 78%
Management of acute coronary syndrome in a case of Behcets disease
Blood Coagulation & Fibrinolysis, 11/03/09
Relevance Score: 78%
Successful treatment of saphenous venous graft thrombus by tirofiban infusion
Heart & Lung; The Journal of Acute and Critical Care, 10/27/09
Relevance Score: 77%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
Cleveland Clinic Journal of Medicine, 12/04/09
Q: Is an ACE inhibitor plus an ARB more effective than either drug alone?
Cleveland Clinic Journal of Medicine, 12/04/09
Interferon-gamma (INF-gamma) release test can detect cutaneous adverse effects to statins
International Journal of Dermatology, 12/03/09
Sponsor
Article Search
Sponsor